Matisse Pharmaceuticals
PrivateLast Round
Series A
Sep 17, 2026
Total Funding Raised
$16.68M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Matisse Pharmaceuticals operates in Healthcare & Life Sciences and is based in Geleen. Its latest recorded funding round was a Series A round in September 2026.
Matisse Pharmaceuticals is a biopharmaceutical company developing therapies for the treatment of sepsis and other inflammatory conditions characterized by elevated levels of circulating cytotoxic histones.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Matisse Pharmaceuticals Comparables
Compare Matisse Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inotrem | 86% | |
| Adrenomed AG | 83% | |
| RevImmune | 81% |
For institutional investors. Book with your work email.
Matisse Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 17, 2026 | ||||
| Grant | Jun 26, 2025 | ||||
| VC Round | Jan 4, 2024 | ||||
| VC Round | Mar 1, 2020 | ||||
| Seed | Nov 15, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Matisse Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mibiton Foundation | Seed |
| Eurostars SME programme | Grant |
| Brightlands Venture Partners | Series A, VC Round, Seed |
| LIOF | Series A, VC Round, Seed |
| Particon B.V. | Seed |
| Netherlands Enterprise Agency | VC Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
$16M round led by Brightlands Venture Partners and LIOF.
- Jul 28, 2026
Monthly visitors grew 205% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
On Sep 18th '26, Matisse Pharmaceuticals B.V is developing isupartob in the Netherlands to neutralize extracellular histones and interrupt the damaging cascade in sepsis as the therapy advances through Phase 2 development.
- receives_financingSep 18, 2026
On Sep 18th '26, Matisse Pharmaceuticals B.V received $16.1M in Series A financing from existing and new shareholders, including Brightlands Venture Partners and LIOF, to advance isupartob sodium through Phase 2 development in sepsis and support related regulatory and manufacturing work in the Netherlands.
For institutional investors. Book with your work email.
Matisse Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Matisse Pharmaceuticals's valuation, stock price, and market status.
Is Matisse Pharmaceuticals a public or private company?
Matisse Pharmaceuticals is a private company.
What is the current stock price of Matisse Pharmaceuticals?
Matisse Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Matisse Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Matisse Pharmaceuticals worth (valuation)?
Valuation information for Matisse Pharmaceuticals is not publicly available.
Can I buy Matisse Pharmaceuticals stock?
Matisse Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Matisse Pharmaceuticals's last funding round?
Matisse Pharmaceuticals's most recent funding round was Series A on September 17, 2026.
Who are the main investors in Matisse Pharmaceuticals?
Key investors in Matisse Pharmaceuticals include Mibiton Foundation, Eurostars SME programme, Brightlands Venture Partners, LIOF, Particon B.V..
Will Matisse Pharmaceuticals IPO soon?
No public IPO plans have been announced for Matisse Pharmaceuticals.
How can I track Matisse Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Matisse Pharmaceuticals's shares on secondary markets.